# Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

> **NCT02637323** · PHASE2 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 81 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** FX006 32 mg
- **DRUG:** TCA IR 40

## Key facts

- **NCT ID:** NCT02637323
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637323, "Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02637323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*